Ascendis Pharma A/S - American (ASND) Reaches New 52-Week High

Moreover, Wms Partners Llc has 0.52% invested in the company for 694,800 shares. As of the end of the quarter Janus Capital Management LLC had sold a total of 35,260 shares trimming its holdings by 5.9%. Leerink's Schwartz predicted early this month that Ascendis Pharma shares could trade up or down as much as 20% on the Versartis results.

In the market the company is trading up by 23.43% percent from yesterday's close. The business's quarterly revenue was down 61.4% compared to the same quarter past year. OppenheimerFunds Inc. purchased a new position in Ascendis Pharma A/S during the first quarter worth about $8,334,000. RA Capital Management LLC grew its holdings in shares of Ascendis Pharma A/S by 3.2% in the second quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company's stock valued at $154,920,000 after purchasing an additional 170,700 shares in the last quarter.

A number of research firms have recently issued reports on ASND. TheStreet lowered shares of Ascendis Pharma A/S from a "c-" rating to a "d" rating in a research report on Thursday, June 15th.

Sell-side analysts are offering a consensus "Buy" rating on shares of Ascendis Pharma A/S (NASDAQ:ASND). Finally, ValuEngine raised shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Saturday, May 27th. Separately, Wedbush's Liana Moussatos reiterated a Buy rating on the stock, while boosting the price target to $65 (from $36). The firm now has a $51.00 price target on the biotechnology company's stock.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 18th.

About 103,310 shares traded. Ascendis Pharma A/S has a 52-week low of $17.15 and a 52-week high of $30.57. Ascendis Pharma A S (NASDAQ:ASND) has risen 96.01% since September 22, 2016 and is uptrending. Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The business had revenue of $0.44 million during the quarter, compared to analysts' expectations of $0.78 million. During the same quarter in the previous year, the company earned ($0.53) earnings per share.

Looking ahead, Ascendis' phase 3 heiGHt trial for TC-hGH treatment of pediatric growth hormone deficiency is on track to finish enrollment in the fourth quarter of this year.

Ascendis Pharma's stock reaction on Friday appeared to surpass Wall Street analyst expectations. If you are accessing this article on another publication, it was copied illegally and republished in violation of USA and global copyright and trademark legislation. The value of the company's investment in Ascendis Pharma A/S - American went from $2,800,000 to $622,000 a change of 77.8% quarter over quarter. The Company is involved in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development.

Latest News